Login / Signup

Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.

N ChartierJ EpsteinM SoudantC DahanM MichaudS Pittion-VouyovitchF GuilleminM DebouverieGuillaume Mathey
Published in: European journal of neurology (2018)
Patients with the most active forms of MS are the most likely to benefit from MITOX in the long term.
Keyphrases
  • multiple sclerosis
  • white matter
  • mass spectrometry
  • ms ms
  • smoking cessation